中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.033 seconds)

    ＥＲＢＢ2 수용체에 선택적으로 결합하는 압타머 및 이의 용도
    3.
    发明公开
    ＥＲＢＢ2 수용체에 선택적으로 결합하는 압타머 및 이의 용도 有权
    APTAMER特异性结合ERBB2受体及其用途

    公开(公告)号：KR1020130012140A

    公开(公告)日：2013-02-01

    申请号：KR1020130002513

    申请日：2013-01-09

    Applicant: 포항공과대학교 산학협력단 ,  대한민국 (식품의약품안전처장)

    Inventor： 이중환 ,  채영찬 ,  김윤동 ,  강현구 ,  임종훈 ,  김종인 ,  김기석 ,  장승기 ,  오일웅 ,  최민정 ,  강원준

    IPC: C12N15/115 ,  A61K48/00 ,  A61P35/00

    Abstract: PURPOSE: A DNA aptamer which specifically binds itself to a breast cancer-related Her2(ERBB2) receptor is provided to effectively suppress metastasis and to diagnose cancer. CONSTITUTION: An ERBB2 aptamer specifically binds itself to ERBB2 and has a base of sequence number 7. The ERBB2 aptamer additionally contains a sequence of sequence number 39 or 40 linked to 5' end and a sequence of sequence number 41 or 42 linked to 3' end. A pharmaceutical composition for treating cancer contains the ERBB2 aptamer as an active ingredient. The cancer includes breast cancer, colon cancer, lung cancer, gallbladder cancer, pancreatic cancer, or gastric cancer. A composition for diagnosing cancer contains the ERBB2 aptamer as an active ingredient.

    Abstract translation: 目的：提供特异性结合乳腺癌相关Her2（ERBB2）受体的DNA适体，以有效抑制转移和诊断癌症。 构成：ERBB2适体与ERBB2特异性结合并具有序列号7的碱基。ERBB2适体还包含连接至5'末端的序列号39或40的序列，以及与3'连接的序列号41或42的序列 结束。 用于治疗癌症的药物组合物含有ERBB2适体作为活性成分。 癌症包括乳腺癌，结肠癌，肺癌，胆囊癌，胰腺癌或胃癌。 用于诊断癌症的组合物含有ERBB2适体作为活性成分。

    ＥＲＢＢ2 수용체에 선택적으로 결합하는 압타머 및 이의 용도
    4.
    发明公开
    ＥＲＢＢ2 수용체에 선택적으로 결합하는 압타머 및 이의 용도 有权
    APTAMER特异性结合ERBB2受体及其用途

    公开(公告)号：KR1020130003071A

    公开(公告)日：2013-01-09

    申请号：KR1020110061939

    申请日：2011-06-24

    Applicant: 포항공과대학교 산학협력단 ,  대한민국 (식품의약품안전처장)

    Inventor： 이중환 ,  채영찬 ,  김윤동 ,  강현구 ,  임종훈 ,  김종인 ,  김기석 ,  장승기 ,  오일웅 ,  최민정 ,  강원준

    IPC: C12N15/115 ,  A61K31/7088 ,  A61P35/00

    CPC classification number: C12N15/115 ,  A61K31/7088 ,  A61K47/60 ,  C12N2310/16 ,  C12N2310/335 ,  C12N2310/3535 ,  C12N2320/30 ,  G01N33/5748 ,  G01N2333/71 ,  G01N2333/91205

    Abstract: PURPOSE: A DNA aptamer which specifically binds to bread cancer-related Her2(ERBB2) receptor and a composition containing the same are provided to effectively suppress and diagnose cancer. CONSTITUTION: An ERBB2 aptamer specifically binds to ERBB2 and contains 5-15 bases which are substituted with a hydrophobic functional group of a naphthyl group, a benzyl group, a pyrrolbenzyl group, or tryptophane at 5` of dUTP(deoxyuracil). The ERBB2 aptamer contains 40-100 bases including bases selected from sequence numbers 1-35. The ERBB2 aptamer contains 40-100 bases including a base of sequence number 7 or 11. The ERBB2 aptamer additionally contains 15-30 bases at 5` end, 3`end, or both ends of a base sequence selected from sequence numbers 1-35. A pharmaceutical composition for treating cancer contains the ERBB2 aptamer as an active ingredient. A composition for diagnosing cancer contains the ERBB2 aptamer as an active ingredient.

    Abstract translation: 目的：提供特异性结合面包癌相关的Her2（ERBB2）受体的DNA适配体和含有该受体的组合物，以有效抑制和诊断癌症。 构成：ERBB2适体与ERBB2特异性结合，并含有5-15个碱基，其在dUTP（脱氧尿嘧啶）5'处被萘基，苄基，吡咯烷基或色氨酸的疏水官能团取代。 ERBB2适体包含40-100个碱基，包括选自序列号1-35的碱基。 ERBB2适体包含40-100个碱基，包括7或11个序列的碱基。ERBB2适体在5'末端，3'末端或两个末端含有15-30个碱基序列，序列号为1-35 。 用于治疗癌症的药物组合物含有ERBB2适体作为活性成分。 用于诊断癌症的组合物含有ERBB2适体作为活性成分。

    뉴클레오린 특이적인 압타머 및 그의 용도
    7.
    发明公开
    뉴클레오린 특이적인 압타머 및 그의 용도 有权
    核蛋白特异性APTAMER及其用途

    公开(公告)号：KR1020130095635A

    公开(公告)日：2013-08-28

    申请号：KR1020127028348

    申请日：2010-09-15

    Applicant: 포항공과대학교 산학협력단 ,  주식회사 포스코

    Inventor： 이중환 ,  김순학 ,  권미진 ,  강현구 ,  류성호 ,  김종인 ,  김윤동 ,  채영찬 ,  장승기 ,  임종훈 ,  이선학 ,  이혜정 ,  장은정 ,  김기석

    IPC: C12N15/115 ,  C12Q1/68 ,  A61K48/00 ,  A61P35/00

    CPC classification number: G01N33/57496 ,  C12N15/115 ,  C12N2310/16 ,  C12N2310/335 ,  A61K48/0066 ,  C12Q1/6876 ,  C12Q2525/205

    Abstract: PURPOSE: A nucleolin-specific aptamer is provided to function as a nucleolin inhibitor and be used as an agent suppressing the dysplasia of a cell, thereby usefully used for the treatment of hyper-proliferative disease such as cancer. CONSTITUTION: A nucleolin-specific aptamer includes a sequence in which at least one thymidine (T) existing in a sequence number 3 is respectively substituted with deformation pyrimidine nucleoside. The deformation pyrimidine nucleoside is one among deoxyuridine (dU) having a hydrophobic group in 5-position, deoxycytidine (dC), uridine (U) and cytidine (C). A sequence number 3 is NGGTGGTGGTGGTTGTGGTGGTGGTGGN. In the sequence number 3, each N is nonexistence or one nucleoside selected from a group consisting of adenosine (A), thymidine (T)/uridine (U), cytidine (C) and guanosine (G).

    Abstract translation: 目的：提供核仁特异性适体作为核仁核酸抑制剂，用作抑制细胞发育不良的药剂，从而有效地用于治疗高增殖性疾病如癌症。 构成：核仁 - 特异性适体包括其中存在于序列号3中的至少一个胸苷（T）分别被变形嘧啶核苷取代的序列。 变形嘧啶核苷是在5-位具有疏水基的脱氧尿苷（dU），脱氧胞苷（dC），尿苷（U）和胞苷（C）中的一种。 序列号3是NGGTGGTGGTGGTTGTGGTGGTGGTGGN。 在序列号3中，每个N不存在或一个选自腺苷（A），胸苷（T）/尿苷（U），胞苷（C）和鸟苷（G））的核苷。

Patent Agency Ranking